| Abstract |
[Abstract] Objective: The value of paroxetine combined with quetiapine in the treatment of schizophrenia with depressive symptoms was explored and its influence on serum homocysteine, HCY level. Methods: 89 schizophrenic patients with depressive symptoms were selected from Fuyang Third Peoples Hospital from July 2020 to December 2022. The patients were divided into experimental group (paroxetine combined with quetiapine, n=44) and control group (pelvic floor muscle rehabilitation training only, n=45) by random number table method, and their clinical efficacy, PANSS score, HAMD score, adverse reactions, and serum Hcy level were compared. Results: Clinical curative effect: The obvious effective rate of the experimental group，which seems clearly higher than the effect of the control group, and it seems clearly statistical significant of the difference（P＜0.05）; PANSS score, HAMD score and serum Hcy level: the PANSS score, HAMD score and serum Hcy level in the experimental group and the control group after 2, 4 and 8 weeks of treatment were lower than those before treatment, and the difference of that, it seems statistically significant (P<0.05). PANSS score , HAMD score and serum Hcy level in the experimental group, which seems clearly lower than those in the control group , after accepting 2, 4 and 8 weeks of treatment in the patients (P<0.01); Adverse reactions: The adverse reactions in the experimental group and the control group was lower, and the total incidence of adverse reactions in the experimental group, it seems lower than that in the control group, but it ssems not statistically significant of all data (P>0.05). Conclusion: Paroxetine combined with quetiapine is effective in the treatment of schizophrenia with depression, so it can be widely used in clinic.
|